According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were ...

Biocon eyes global insulin leadership as rivals pivot to GLP-1 therapies, betting on capacity gaps, pricing advantage and ...

Biocon aims to become the world's leading insulin company, capitalising on larger pharmaceutical rivals' strategic shift ...

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Biocon, a biopharma giant, is escalating its artificial intelligence adoption across all operations to expedite drug ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon’s fair value estimate has been adjusted slightly, moving from ₹421.60 to ₹420.74, a change of less than 1% that keeps the price target broadly in line with earlier expectations. Analysts ...

Biocon's Siddharth Mittal steps down as MD & CEO; Shreehas Tambe, a 30-year company veteran with 61 patents, takes over from April 1.

Viatris is leaving the biosimilar field just months after winning the landmark FDA approval for the first interchangeable biosimilar product. Biocon Biologics, a subsidiary of Biocon, will buy Viatris ...

Biocon share price has rallied over 20% in one month and has gained 17% in three months. The stock has surged 28% in six months, and has risen 14% on a year-to-date (YTD) basis. Biocon shares have ...

Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Profit rises 71% YoY to Rs 144 crore Biocon Biologics share which constitutes 45% of revenues reported 29% YoY growth to Rs ...